SCHEMBL22493432

SCHEMBL22493432

Cc1ccccc1-c1cccc(CCNC(C)(C)C)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 1/20 0.36
PDCD1LG2 Q9BQ51 1/20 0.34
CD274 Q9NZQ7 1/20 0.34
PTPN1 P18031 2/20 0.34
CYP1A2 P05177 5/20 0.34
CLK4 Q9HAZ1 4/20 0.34
SHMT1 P34896 1/20 0.34
CYP2C19 P33261 4/20 0.33
CYP2D6 P10635 3/20 0.33
ALOX15 P16050 2/20 0.33
ALDH1A1 P00352 2/20 0.33
HSD17B10 Q99714 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA1 P30542 1/20 0.33
IDO1 P14902 1/20 0.33
METAP2 P50579 1/20 0.33
USP2 O75604 1/20 0.33
APEX1 P27695 1/20 0.33
CASP7 P55210 1/20 0.33
CTSL P07711 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22493438 0.84 CNR2 (0.43) PDCD1LG2CD274PTPN1SHMT1CYP2D6
SCHEMBL22480758 0.78 TRPV3 (0.39) ALDH1A1HSD17B10CTSLCTSBCTSS
SCHEMBL17886911 0.77 SMN1; SMN2 (0.46) ALDH1A1CTSLCTSBCTSSCTSK
SCHEMBL22480829 0.76 TRPV3 (0.43) GRM2ADORA2AADORA1IDO1METAP2
SCHEMBL22493739 0.75 PDE10A (0.49) CYP1A2CYP2C19CYP2D6CTSLCTSB
SCHEMBL17039118 0.75 HEXA (0.41) GRM2PTPN1CYP1A2CLK4CYP2C19
SCHEMBL22493866 0.74 CNR2 (0.39) SHMT1ALOX15ALDH1A1HSD17B10CTSL
SCHEMBL22493894 0.74 SCN9A (0.44) ALDH1A1CTSLCTSBCTSSCTSK
SCHEMBL22481211 0.73 EPHX2 (0.36) ALDH1A1CTSLCTSBCTSSCTSK
SCHEMBL22493399 0.72 CYP3A4 (0.36) PDCD1LG2CD274CYP2D6ALOX15ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024137506-A1 COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS CURASEN THERAPEUTICS, INC. (US) 2024-06-27 WO disclosed
WO-2023225021-A1 COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) CURASEN THERAPEUTICS, INC. (US) 2023-11-23 WO disclosed
WO-2020198466-A9 BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME CURASEN THERAPEUTICS, INC. (US) 2020-12-30 WO disclosed
WO-2020198466-A1 BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME CURASEN THERAPEUTICS, INC. (US) 2020-10-01 WO disclosed